Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Vladimir Vladimirov/E+ via Getty Images Topline Summary and Update Cardiff Oncology (NASDAQ:CRDF) is a cancer-focused biotech working on developing a drug that exploits a novel target, particularly in colorectal cancer. In my past articles, I have been lukewarm to slightly pessimistic about their findings presented to date and their overall outlook. But recent news has sent them on a meteoric rise, and the ensuing roller coaster has readers asking me directly for input on this company. So let's examine  ...